Olcegepant

Olcegepant (INN,[1] code name BIBN-4096BS) is a calcitonin gene-related peptide receptor antagonist being studied as a potential treatment for migraines.[2]

Olcegepant
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H47Br2N9O5
Molar mass869.660 g·mol−1
3D model (JSmol)

A 2013 meta-analysis found olcegepant and telcagepant were effective and safe compared to placebo.[3]

See also

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 48" (PDF). World Health Organization. pp. 256–7. Retrieved 20 March 2017.
  2. Tfelt-Hansen P, Olesen J (April 2011). "Possible site of action of CGRP antagonists in migraine". Cephalalgia. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046.
  3. Yao G, Yu T, Han X, Mao X, Li B (April 2013). "Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis". Neural Regeneration Research. 8 (10): 938–47. doi:10.3969/j.issn.1673-5374.2013.10.009. PMC 4145922. PMID 25206386.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.